Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
2.85 USD -1.04% Intraday chart for DiaMedica Therapeutics Inc. -6.25% +0.35%
May. 23 DiaMedica Therapeutics Inc. Elects Rick Pauls as Director CI
May. 09 Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director
CI
Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
BU
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
BU
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment
MT
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
BU
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
CI
DiaMedica Therapeutics Inc. Announces Executive Changes
CI
DiaMedica Therapeutics Files $100 Million Mixed Shelf
MT
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating
MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating
MT
Transcript : DiaMedica Therapeutics Inc., 2023 Earnings Call, Mar 20, 2024
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
BU
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
BU
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer
MT
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
BU
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer
CI
Transcript : DiaMedica Therapeutics Inc., Q3 2023 Earnings Call, Nov 14, 2023
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. News DiaMedica Therapeutics Inc.